Page last updated: 2024-08-25

tetrandrine and Granulocytic Leukemia, Chronic

tetrandrine has been researched along with Granulocytic Leukemia, Chronic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, T; Gan, YC; Gu, Y; Tang, JF; Xie, YY; Xu, F; Xu, GB; Xu, RZ; Xu, XH; Zhao, XY; Zhou, H	1

Other Studies

1 other study(ies) available for tetrandrine and Granulocytic Leukemia, Chronic

Article	Year
Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis. Journal of Zhejiang University. Science. B, 2012, Volume: 13, Issue:11 Topics: Administration, Oral; Animals; Benzamides; Benzylisoquinolines; beta Catenin; Cell Growth Processes; Citrates; Down-Regulation; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Fusion Proteins, bcr-abl; G1 Phase Cell Cycle Checkpoints; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Neoplastic Stem Cells; Piperazines; Pyrimidines; Random Allocation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Xenograft Model Antitumor Assays	2012

Article

Year

Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.

Journal of Zhejiang University. Science. B, 2012, Volume: 13, Issue:11

Topics: Administration, Oral; Animals; Benzamides; Benzylisoquinolines; beta Catenin; Cell Growth Processes; Citrates; Down-Regulation; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Fusion Proteins, bcr-abl; G1 Phase Cell Cycle Checkpoints; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Neoplastic Stem Cells; Piperazines; Pyrimidines; Random Allocation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Xenograft Model Antitumor Assays

2012